AutoGenomics Gets FDA OK for Warfarin MDx Assay | GenomeWeb
NEW YORK (GenomeWeb News) – AutoGenomics today announced that it has received US Food and Drug Administration clearance to market its Infiniti 2C9-VKORC1 Multiplex Assay for warfarin sensitivity.
The Carlsbad, Calif.-based firm becomes the second firm to gain FDA clearance for a molecular-based assay for warfarin. In September, the agency approved Nanosphere’s Verigene Warfarin Metabolism Nucleic Acid Test, which runs on that company’s Verigene platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.